56
Participants
Start Date
June 30, 2011
Primary Completion Date
May 31, 2012
Study Completion Date
November 30, 2012
Afamelanotide
NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
Narrow-Band UVB Light Treatment
To be administered 3 times/week for 6 months. 72 treatments in total.
The Mount Sinai School of Medicine, New York
Henry Ford Medical Center, Detroit
Lead Sponsor
Clinuvel Pharmaceuticals Limited
INDUSTRY